Kenya received 21,000 starter doses of Lenacapavir, marking a significant step in the country’s HIV prevention strategy as the Ministry of Health moves to introduce the long-acting injectable medicine.
In a statement issued on February 17, 2026, the Ministry of Health said the doses will support the initial roll-out of the new HIV prevention option in selected counties.
The ministry described the intervention as part of Kenya’s continued efforts to curb new infections, particularly among populations most at risk.
The ministry noted that Kenya currently has an HIV prevalence of about 3.7 per cent, with approximately 1.34 million people on anti-retroviral treatment. It highlighted a worrying trend in new infections.
Lenacapavir is a long-acting injectable HIV prevention option known as Pre-Exposure Prophylaxis, or PrEP. The Ministry of Health emphasised that the medicine is intended for people who are HIV negative.
Comments 0
Sign in to join the conversation
Sign In Create AccountNo comments yet. Be the first to share your thoughts!